10 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02225 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Calu-6 | Lung cancer | Activity : ~90% survival rate at 10 µM |
| dbacp02226 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Calu-6 | Lung cancer | Activity : <20% survival rate at 100 µM |
| dbacp02227 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Jurkat | Blood cancer | Activity : 100% survival rate at 10 µM |
| dbacp02228 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Jurkat | Blood cancer | Activity : 0% survival rate at 100 µM |
| dbacp02229 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | SNU-601 | Gastric cancer | Activity : ~80% survival rate at 10 µM |
| dbacp02230 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | SNU-601 | Gastric cancer | Activity : 10% survival rate at 100 µM |
| dbacp02270 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | B16-F10 | Skin cancer | LC50 : 1.75 µM |
| dbacp02271 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | RENCA | Renal cancer | LC50 : 1.3 µM |
| dbacp02272 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | 4T1 | Breast cancer | LC50 : 6.2 µM |
| dbacp02273 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | WM1158 | Skin cancer | LC50 : 4.1 µM |